18 recruiting. 18 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Recruiting 18 |
| Phase 2 | 6 | Recruiting 6 |
Follow Hematologic Malignancy: new trials by email Literature Review of Hematologic Malignancy trials Research Report on Hematologic Malignancy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ph 1 Study Long-acting Interleukin-7, Efineptakin Alfa, to Enhance Immune Reconstitution After PTCy Efineptakin Alfa (rhIL-7-hyFc) - Hematologic Malignancy | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 12 | 2026-12-01 | 2026-11-17 |
| CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine - Relapsed Pediatric ALL, Hematopoietic Cell Transplantation | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 70 | 2026-10-03 | 2026-08-28 |
| Clinical Study of the Safety and Efficacy of Allogeneic TCR-enhanced Vδ2 T Cell in Patients With Malignant Tumors. Allogeneic TCR-enhanced Vδ2 T cell Injection, Cyclophosphamide injection, Fludarabine Injection - Hematologic Malignancy, Solid Tumor | Phase 1 / Phase 2 | Recruiting | Chinese PLA General Hospital | 24 | 2026-06-05 | 2026-06-08 |
| CD45RA-depleted DLI for the Treatment of Refractory/Persistent Viral Infections After Haploidentical Transplantation CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy, Haplo-identical HCT | Phase 1 / Phase 2 | Recruiting | Ruijin Hospital | 30 | 2026-06-01 | 2026-06-23 |
| TCRαβ-depleted Progenitor Cell Graft With Early Memory T-cell DLI, Plus Selected Use of Blinatumomab, in naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Thymoglobulin, Cyclophosphamide, Fludarabine - Hematologic Malignancy | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 30 | 2025-09-25 | 2026-06-02 |
| Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies G-CSF, Decitabine, Venetoclax - Myeloid Malignancy, Hematologic Malignancy | Phase 1 | Recruiting | University of Alabama at Birmingham | 20 | 2025-07-17 | 2026-03-04 |
| CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors Fludarabine + Cyclophosphamide + CD7-specific CAR-T Cells - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 80 | 2024-12-31 | 2024-12-06 |
| Prophylactic CD45RA-depleted DLI After Haploidentical Transplantation/RIC CD45RAneg cells, prepared from mononuclear cell leukapheresis by CliniMACS® technology - Hematologic Malignancy, Haplo-identical Stem Cell Transplantation | Phase 1 | Recruiting | University Hospital, Geneva | 12 | 2024-11-26 | 2025-02-13 |
| Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia WBC100 QD - AML (Acute Myelogenous Leukemia, Relapsed Acute Myelogenous Leukemia | Phase 1 | Recruiting | Hangzhou Weben Pharma Co., Ltd | 36 | 2024-11-03 | 2026-10-16 |
| CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies Fludarabine, Cyclophosphamide, CD70-CAR T cell infusion (Autologous) - Hematologic Malignancy, ALL, Childhood | Phase 1 | Recruiting | St. Jude Children's Research Hospital | 18 | 2024-10-16 | 2026-01-23 |
| TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies TGRX-1942 - Non Small Cell Lung Cancer, Advanced Solid Tumor | Phase 1 | Recruiting | Shenzhen TargetRx Co., Ltd. | 90 | 2024-07-08 | 2025-02-24 |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) TRX103 - Hematologic Malignancy, GvHD | Phase 1 | Recruiting | Tr1X, Inc. | 36 | 2024-04-08 | 2025-04-15 |
| TGRX-814 Chinese Phase I/II in Patients With Hematological Malignancies TGRX-814 - Hematologic Malignancy, Non Hodgkin Lymphoma | Phase 1 / Phase 2 | Recruiting | Shenzhen TargetRx Co., Ltd. | 30 | 2024-03-06 | 2024-04-10 |
| Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies autologous hematopoietic stem cells added to planned CAR T - Hematologic Malignancy, Large B-cell Lymphoma | Phase 1 | Recruiting | Joshua Sasine, MD, PhD | 20 | 2024-03-02 | 2026-08-10 |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia Ziftomenib, Fludarabine, Idarubicin - AML, AML With Mutated NPM1 | Phase 1 | Recruiting | Kura Oncology, Inc. | 171 | 2024-02-22 | 2026-08-20 |
| CD45RA Depleted DLI After TCRα/β Depleted Haploidentical HCT CD45RA depleted donor lymphocyte infusion (DLI) - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | University Hospital Tuebingen | 60 | 2023-04-27 | 2025-04-27 |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies Tagraxofusp, Fludarabine, Cytarabine - Hematologic Malignancy, AML | Phase 1 | Recruiting | Therapeutic Advances in Childhood Leukemia Consortium | 54 | 2022-11-11 | 2024-12-06 |
| Study Evaluating the Safety and the Efficacy of Human T Lymphoid Progenitor (HTLP) Injection to Accelerate Immune Reconstitution After Umbilical Cord Blood (UCB) Transplantation in Adult Patients With Hematologic Malignancies (HTLP-ONCO) Human T Lymphoid Progenitor (HTLP) injection - Hematologic Malignancy | Phase 1 / Phase 2 | Recruiting | Assistance Publique - Hôpitaux de Paris | 10 | 2022-02-16 | 2026-08-12 |
Hematologic Neoplasms (18) · Leukemia, Myeloid, Acute (6) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Myelodysplastic Syndromes (3) · Leukemia (2) · Recurrence (2) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma, Non-Small-Cell Lung (1) · Graft vs Host Disease (1) · Hodgkin Disease (1) · Leukemia, Biphenotypic, Acute (1) · Leukemia, Myeloid (1) · Leukemia, Myelomonocytic, Chronic (1) · Lymphoma (1)
Hematologic Diseases (18) · Hemic and Lymphatic Diseases (18) · Neoplasms (18) · Neoplasms by Site (18) · Neoplasms by Histologic Type (9) · Leukemia (8) · Immune System Diseases (6) · Immunoproliferative Disorders (6) · Leukemia, Lymphoid (6) · Leukemia, Myeloid (6) · Lymphatic Diseases (6) · Lymphoproliferative Disorders (6) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Bone Marrow Diseases (3)
fludarabine (7) · Cyclophosphamide (5) · Granulocyte Colony-Stimulating Factor (3) · Mesna (3) · Cytarabine (2) · Filgrastim (2) · Melphalan (2) · Thiotepa (2) · Antilymphocyte Serum (1) · Azacitidine (1) · Calcium Dobesilate (1) · Decitabine (1) · Dexamethasone (1) · Hydrocortisone (1) · Idarubicin (1)
St. Jude Children's Research Hospital (3) · Shenzhen TargetRx Co., Ltd. (2) · Assistance Publique - Hôpitaux de Paris (1) · Chinese PLA General Hospital (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hangzhou Weben Pharma Co., Ltd (1) · Joshua Sasine, MD, PhD (1) · Kura Oncology, Inc. (1) · Ruijin Hospital (1) · Therapeutic Advances in Childhood Leukemia Consortium (1) · Tr1X, Inc. (1) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · University Hospital Tuebingen (1) · University Hospital, Geneva (1) · University of Alabama at Birmingham (1)
United States (9) · China (6) · Australia (1) · France (1) · Germany (1) · Italy (1) · Spain (1) · Switzerland (1)
Swati Naik, MBBS (2) · Adam Lamble, MD (1) · Bo Jiang, MD (1) · Brandon Triplett, MD (1) · Jianxiang Wang, MD (1) · Joshua Sasine, MD, PhD (1) · Maria Grazia Roncarolo, MD (1) · Mei Heng, M.D., Ph.D (1) · Omer A Jamy, MD (1) · Sayeef Mirza, MD (1)
2019 (1)